BioLink-2018 is under clinical development by Protheragen and currently in Phase I for Unspecified B-Cell Lymphomas. According to GlobalData, Phase I drugs for Unspecified B-Cell Lymphomas does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BioLink-2018 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BioLink-2018 overview
BioLink-2018 is under development for the treatment of b-cell lymphomas. The drug candidate is administered through oral route and acts by targeting bruton tyrosine kinase (BTK).
Protheragen overview
Protheragen is primarily focuses on the research and development of novel drugs. The company’s main activities include intermediary services, equity investment, and program incubation. Its portfolio includes projects in various stages of development, from discovery to Phase III, with a focus on antibody therapy, recombinant protein therapy, oncolytic virotherapy, small molecules, cell therapy, and gene therapy. Protheragen develops numerous potential treatments for conditions such as cancer, asthma, sepsis, fibrosis, neurological diseases, and more. Its products are designed for use in the healthcare industry, specifically in the treatment of various diseases. The company seeks partnerships for equity investment, intermediary services, and project incubation, indicating a potential network of collaborators. Protheragen is headquartered in New York city, New York, the US.
For a complete picture of BioLink-2018’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
